VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 1730 · 116th Congress

Cancer Drug Parity Act of 2019

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

BHD HigginsSponsor
170 cosponsors · 105 D, 65 R
GBR Bilirakis ABD Bera TCR Cole PDD DeFazio BFR Fitzpatrick BGR Guthrie AHD Hastings WHR Hurd PKR King DKD Kilmer RKD Khanna MMR McCaul DMD Matsui JND Nadler END Norton POR Olson DWD Wasserman Schultz RLR Latta SMD Moulton PCR Cook GGR Gianforte DPD Price CPD Pingree KRD Rice ESR Stefanik SCD Cohen KMR Marchant LBR Bucshon JRD Raskin RGD Grijalva TWR Walberg JGD Garamendi JHR Hice MBR Bost YCD Clarke RDR Davis LRD Roybal-Allard RWR Wittman ECD Case BMR Mast JSD Sarbanes STR Tipton BPR Posey BRD Rush JKD Kennedy DYR Young NBD Barragán LGR Gooden MGR Guest AKD Kuster EBD Blumenauer ACD Craig GGR Grothman BJR Johnson TKR Kelly BLR Long SMD Maloney JSD Speier KAR Armstrong DDD Dingell CMR McMorris Rodgers GMD Moore DMR McKinley ASD Schiff SSR Stivers ASR Scott BTD Thompson SWD Wild JCD Castro SPR Palazzo MGR Gallagher SJD Jackson Lee SDR Duffy PTD Tonko VHR Hartzler ESD Swalwell BCR Carter GMD Meeks JBR Bergman MDD Doyle HGR Griffith CMD Maloney DCR Crenshaw JYD Yarmuth CHR Higgins HRD Rouda RHR Hudson AKD Kim EED Engel FSR Sensenbrenner LBD Blunt Rochester JKR Katko TOD O’Halleran JRR Rutherford MAR Amodei SBR Brooks DSD Soto MSD Scanlon SLD Lynch MTR Turner BFR Flores AGD Green PMR Mitchell ESD Slotkin JCD Cunningham JJR Joyce CPD Pappas GTR Thompson TMD Malinowski ASD Sires JVD Van Drew JGD Gottheimer DJR Joyce GND Napolitano ZLD Lofgren DNR Newhouse LSR Smucker KSD Schrier ELD Luria BWD Watson Coleman MWR Waltz RAR Abraham SBD Bonamici JMD McGovern SWR Womack MCD Cartwright WSR Steube CAD Allred RSR Spano BBD Boyle JMR Moolenaar JCD Chu TBR Burchett ECD Cleaver JHD Himes BWR Westerman AAD Adams CAD Axne JBD Beatty GCD Connolly GCD Cisneros TCD Cox LDD Doggett SDD Davis TDD Deutch MDD DeSaulnier DED Evans VED Escobar LFD Frankel CHD Houlahan MKD Kaptur WKD Keating DLD Lipinski ALD Levin BMD McCollum SMD Murphy JMD Morelle LMD McBath EPD Perlmutter MPD Pocan CRD Ruppersberger TRD Ryan MRD Rose DSD Scott TSD Suozzi HSD Stevens MTD Takano LTD Trahan DTD Trone LUD Underwood

17 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.

What it does: CRS summary · Introduced in House · Mar 13, 2019

Cancer Drug Parity Act of 2019

This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Cancer Drug Parity Act of 2019

Latest action (Mar 14, 2019): Referred to the Subcommittee on Health.

Policy area: Health · Origin: House · Introduced: Mar 13, 2019

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.